A 2024 real-world, propensity-matched cohort study of IBD patients aged 50 or older with CV comorbidities reported no significant difference in the incidence of acute HF between JAK inhibitor and TNF inhibitor users (0.76 [95% CI: 0.33–1.75] [78]). The gene discussed is TNF; the disease is inflammatory bowel disease.